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Travelers have the potential both to acquire and to spread dengue virus infection. The incidence of dengue
fever (DF) among European travelers certainly is underestimated, because few centers use standardized di-
agnostic procedures for febrile patients. In addition, DF is currently not reported in most European public
health systems. Surveillance has commenced within the framework of a European Network on Imported
Infectious Disease Surveillance (TropNetEurop) to gain information on the quantity and severity of cases of
dengue imported into Europe. Descriptions of 294 patients with DF were analyzed for epidemiological in-
formation and clinical features. By far the most infections were imported from Asia, which suggests a high
risk of DF for travelers to that region. Dengue hemorrhagic fever occurred in 7 patients (2.4%) all of whom
recovered. Data reported by member sites of the TropNetEurop can contribute to understanding the epide-
miology and clinical characteristics of imported DF.
Dengue fever (DF) is endemic in most tropical parts
of the world, many of which are popular tourist des-
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tinations. The incidence of epidemic and endemic den-
gue has increased substantially, notably in the Americas,
where, since 1977, various epidemics have occurred
[1–4]. It is estimated that the current annual global
incidence of dengue infection is 50–100 million patients
per year [5]. Among the factors that have been impli-
cated in the current increase in the incidence of dengue
are international travel, which introduces new strains
to different parts of the world; urbanization; overpop-
ulation; crowding; poverty; and a weakened public-
health infrastructure [6].
Structured data on the epidemiology and clinical
course of dengue infection in travelers are rare. Al-
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though case reports on imported dengue are relatively frequent,
they do not allow for an estimation of the risk of illness for
travelers. Various case reports regarding dengue infections in
international travelers returning from areas of endemicity have
been published [2, 4, 7–13]. In a small number of systematic
studies on this topic, serological evidence of recent dengue in-
fection was found in 7%–45% of febrile patients after they had
returned from areas of endemicity [14–17]. A retrospective study
of a small cohort of Swiss travelers showed a surprisingly high
prevalence of antibodies to dengue virus (8%) among symptom-
atic patients [18]. These results were supported further by a
prospective study of 130 febrile patients who had returned from
areas where dengue is endemic, which found a prevalence of
6.9% [16]. In the latter study, 9 of 10 patients who tested positive
for dengue had acquired the infection in Southeast Asia. Similar
to the sparse data on the true incidence of DF among travelers,
little is known about the clinical spectrum of DF and the pro-
portion of subclinical infections in this group. Studies from
areas of endemicity suggest that 14%–87% of all dengue in-
fections manifest few or atypical symptoms [19–21]. Yet the
proportion of subclinical dengue infections among travelers is
of importance, because it has been suggested that infection with
one serotype of dengue virus can predispose for the develop-
ment of dengue hemorrhagic fever (DHF) and/or dengue shock
syndrome on reinfection with another serotype [22].
The lack of surveillance data for imported cases of infectious
diseases in Europe prompted the founding in February 1999 of
the European Network on Imported Infectious Disease Surveil-
lance (TropNetEurop), which is an electronic network of clinical
sites related to imported infectious diseases. The network is de-
signed to effectively detect emerging infections of potential re-
gional, national, or global impact at their point of entry into the
European population. Sentinel surveillance reporting is carried
out by participating sites by use of a standardized and comput-
erized reporting system. Immediate transmission of anonymous
patient and laboratory data to the central database ensures the
timely detection of sentinel events. Membership is voluntary
and self-selected by participating centers and is monitored by
the steering committee of the network. Although the organi-
zation of the network does not guarantee that data collected
will be representative for Europe, most major referral centers
on the continent are represented: there are 37 clinical sites
throughout 14 European countries. From the beginning, DF
has been one of the major targets for this network. The present
article summarizes results from the first years of sentinel sur-
veillance for imported DF.
PATIENTS, MATERIALS, AND METHODS
Member sites of the imported infectious disease network
TropNetEurop treat ∼51,000 patients per year. During the 3-
year period from January 1999 through December 2001, 294
patients with DF were reported by 24 sites within the network.
The final diagnosis was qualified in every patient by the re-
porting center, which stated the diagnosis as “suspected,”
“probable,” or “confirmed.” For a diagnosis of “confirmed”
dengue, the virus was detected by isolation or immunohisto-
chemical analysis of necropsy tissue specimens or a type-specific
plaque-reduction neutralization test revealed at least a 4-fold
increase in antibody titers [23]. A variety of test kits were used
by the reporting centers, all of which are established and widely
used assays. In-house kits were not used. In all serological meth-
ods, cross-reactions with other flaviviruses might have inter-
fered with results, with the ELISA method being particularly
vulnerable. Yellow fever vaccination, especially, may play a cru-
cial role here, since many travelers to areas where dengue is
endemic also receive that vaccine before departure. Cases for
which samples were positive for IgM antibody alone were re-
ported as “probable” dengue infections. “Suspected” infections
had the diagnosis established on clinical grounds only. A stan-
dardized, anonymous questionnaire was used for data collec-
tion. Reported case patients were sorted according to the fol-
lowing 2 categories: (1) patient classification (immigrant/ref-
ugee, foreign visitor, European living in Europe, or European
living outside Europe) and (2) reason for travel (tourism, busi-
ness, immigration, military, research/education, missionary/
volunteer/humanitarian aid, visiting relatives/friends, or other).
Travel and case histories were analyzed for clinical and epi-
demiological features of the infection. Individual data points
were stored in a computerized database (Access; Microsoft) and
were analyzed by means of SAS (SAS Institute). Patients with
a diagnosis of suspected dengue infection were excluded from
the present analyses. Analyses with a clinical end point also
excluded patients with multiple infections.
RESULTS
Of the 309 reported patients with DF during the period eval-
uated, 294 had no other diagnosis reported; 212 (72.1%) had
confirmed cases, according to the definition used by the sur-
veillance network. A further 26 patients (8.8%) were classified
as having probable cases, and 25 (8.5%) as having suspected
cases. The diagnosis status was unknown for 26 patients (8.8%).
Patients with suspected dengue and those with unknown di-
agnostic status were excluded from further analysis. Men con-
stituted the majority (166 patients [56.5%]). The average age
of all reported patients was 35.5 years (median, 34 years; range,
1–68 years). The overwhelming majority of patients (252
[85.7%]) were classified as Europeans; 240 patients (81.6%)
were living in Europe, and 12 (4.1%) were living elsewhere.
Only small proportions of patients were foreign visitors (11
[3.7%]) or immigrants (19 [6.5%]). No classification was pro-
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Figure 1. Geographical regions where dengue fever was acquired by 282 travelers living in Europe. Data are percentages.
vided for 1 patient (0.3%). Reasons for travel differed for Eur-
opeans and immigrants: the former traveled for tourism (77.5%
of patients), business reasons (9.2%), missionary work (5.8%),
research (3.3%), visits to relatives or friends (2.1%), or other
reasons; for the small group of immigrants, reasons for travel
were visits to relatives or friends (79% of patients), immigration
(15.8%), or tourism (5.2%).
Geographical regions of infection with DF are shown in fig-
ure 1. Indonesia and South and Southeast Asia were by far the
largest contributors of patients, followed by the Americas. The
temporal distribution of cases of dengue imported into Europe
is shown in figure 2. The total number of observations increased
during the 3-year reporting period, and the proportions of such
cases imported from certain areas also changed during that
time. The proportion of patients with cases acquired in South-
east Asia increased from 20.7% in 1999 to 35.5% in 2001, and
a similar tendency was observed for patients with cases acquired
in India (from 17.2% in 1999 to 21.8% in 2001). The pro-
portion of patients with cases acquired in the Americas de-
creased from 31% in 1999 to 16.2% in 2001. Of the 269 patients
reported to have dengue only, 3.3% were reported to be asymp-
tomatic. Symptom information was given for 250 patients; signs
and symptoms are presented in table 1. The majority of patients
had a combination of fever, headache, fatigue, and musculo-
skeletal symptoms (arthralgia and myalgia). However, a wide
variety of other symptoms were frequently noted. Treatment
was symptomatic for all patients; most patients (75.9%) re-
ceived treatment as outpatients. Those patients who were ad-
mitted to a hospital stayed for an average of 5 days (range,
2–11 days). Clinical complications were reported in 8 (3.2%)
of 250 patients. Five patients (2%) developed signs of DHF,
with petechial bleeding and thrombocytopenia. Two of 10 pa-
tients had signs of hepatitis, 1 from an extended fatigue syn-
drome. All patients recovered.
DISCUSSION
DF is progressively making its way from being “one of the great
neglected diseases of mankind” [24] toward being acknowl-
edged as one of the world’s major emerging infectious diseases.
In 1998, a total of 558,000 infections and 15,000 deaths due
to DF were reported by member states of the World Health
Organization (WHO), which corresponds to a case-fatality rate
of 2.7% [25]. Cases of DF are not notified to public health
officials in most countries. As a consequence, actual numbers
of both deaths and cases of disease due to dengue virus are
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Figure 2. Patients with cases of dengue fever imported into Europe, by month and year reported. Months are indicated as numbers, years as the
last 2 digits of the year.
certainly much higher than those reported to the WHO. The
marked increase in the problems that dengue epidemics and
endemics pose for tropical areas is reflected in travelers’ in-
creasing risk of acquiring the infection [26]. There is a con-
siderable lack of data regarding the actual frequency of this
infection among international travelers. The data presented
here provide some insight into the epidemiology and clinical
presentation of DF in travelers.
The overwhelming majority of patients who presented with
DF were Europeans who traveled for tourism. Of patients with
dengue who presented to TropNetEurop sites, those who had
traveled to Asia were by far the highest percentage: 23.3% of
patients had visited Southeast Asia, 22.9% had visited the In-
dian subcontinent, and 6.5% had visited Indonesia (figure 1).
The proportion of patients who had acquired infection in the
Americas was slightly smaller: 38.2% of all patients. One patient
was reported who had acquired infection in Hawaii in 2000;
this case heralded the later outbreak of DF on Maui [27]. It is
difficult to derive risk estimates from these data. Numbers of
patients reported throughout the network lack a true denom-
inator, because no data are available regarding the travel activ-
ities of the general population to which the patients belong. A
large number of patients returning from Asia with DF may only
reflect increased travel activity to that continent and not an
increased risk for infection. However, reports from the World
Tourism Organization from 1999 and 2000 have shown that
16%–21% of European travelers visited Southeast Asia and only
6%–8% visited India [28, 29]. This suggests a comparatively
high relative risk of acquiring DF in latter region, whereas
numbers from Southeast Asia appear to reflect the high rate
of tourism to that area. The low number of infections that were
acquired in Africa is consistent with all previous epidemiolog-
ical data [2, 4, 7–13]. The 2 African countries contributing the
most patients were Ghana and Kenya, which, again, most likely
reflects the travel habits of tourists.
There is no doubt that dengue importation into Europe
shows a seasonal pattern (figure 2). Most likely, this reflects
the migratory habits of European tourists rather than true var-
iations in disease activity. The increase in the total number of
dengue observations per year during the 3-year reporting pe-
riod may simply reflect an increased awareness of the disease
and its signs by the clinicians who are involved in TropNet-
Europ and who regularly receive its reports. Local changes in
the incidence of dengue infection were considerable: the pro-
portion of patients with cases acquired in East Asia increased
from 20.7% in 1999 to 35.5% in 2001, and a similar tendency
was observed for patients with cases acquired in India (17.2%
in 1999 to 21.8% in 2001). The proportion of patients with
cases acquired in the Americas decreased from 31% in 1999 to
16.2% in 2001. This may reflect changes in travel patterns, but
reports from the World Tourism Organization do not indicate
major shifts in the travel activity of Europeans away from the
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Table 1. Signs and symptoms in 250
Europeans and immigrants with den-
gue fever.
Symptom
No. (%)
of patients
Fever 215 (86)
Headache 148 (59.2)
Fatigue 108 (43.2)
Myalgia or arthralgia 106 (42.4)
Rash 73 (29.2)
Diarrhea 51 (20.4)
Vomiting 20 (8.0)
Respiratory complaints 15 (60)
Neurological complaints 6 (24)
Psychological complaints 5 (20)
Otitis 22 (8.8)
Genitourinary 3 (1.2)
Other 30 (12.0)
NOTE. Multiple entries are possible.
Americas and toward Asia [28, 29]. More likely, these numbers
reflect the activity of dengue in the regions that European trav-
elers frequent. Thus, an increase in the number of reports of
DF in patients returning from an area of endemicity can serve
as an early indicator of increased disease activity.
Symptoms commonly associated with dengue, such as fever,
myalgia, arthralgia, and exanthema, can be helpful in making
the diagnosis, when present, but the absence of typical symp-
toms does not exclude infection (table 1). Most patients with
dengue in this study were symptomatic and reported fever and
headache. Myalgias, fatigue, and rashes were common, as well
as diarrhea. Thus, the diagnosis of dengue virus infection
should be considered for patients who present with a broad
variety of symptoms and who reside in or have recently traveled
to dengue-endemic regions. Dengue has a short incubation
period; thus, in this study, symptoms tended to begin before
or just after the return from the journey (median, 1 day after
return). The course of illness was benign in most patients.
However, clinical complications consistent with DHF were re-
ported in 5 patients (2%). These patients were treated on an
inpatient basis; therapy included platelet substitution and in-
tensive care management for 4 patients. Fortunately, all patients
recovered.
In conclusion, the data reported by member sites of
TropNetEurop can contribute to the understanding of the ep-
idemiology and clinical characteristics of imported DF, espe-
cially since this infection is not notified to public-health officials
in most European countries. It is obvious that the surveillance
network cannot guarantee that data collected will be represen-
tative for Europe, because membership in the network is self-
selected. However, in most European countries, medical ser-
vices for immigrants and returning travelers are offered
primarily at specialized centers. The capacity of the network to
detect and report outbreaks within very short time has been
demonstrated elsewhere [30]. Also, previous work has shown
that the network oversees 10%–12% of all patients with im-
ported infections in Europe [31]. It is also the only clinical
network that collects data on imported infectious diseases
throughout European. As such, the network has the capacity
to provide valuable information for clinical practice and pre-
travel counseling. Continuous monitoring of reported data will
add information on epidemiological changes in affected areas,
which is urgently needed because of increasing travel activity
and migration.
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